Gaudium IVF IPO marked the public offering of Gaudium IVF and Women Health Limited, a healthcare company specialising in fertility treatment and women’s healthcare services. The company offers assisted reproductive technology (ART) solutions through a network of fertility centres supported by specialised medical infrastructure and experienced healthcare professionals.
Its healthcare services include in-vitro fertilisation (IVF), intrauterine insemination (IUI), intracytoplasmic sperm injection (ICSI), fertility preservation, diagnostic services, pregnancy care, gynaecological treatments, and other reproductive healthcare solutions. The company aims to provide comprehensive fertility care by combining advanced medical technology with personalised patient treatment.
Gaudium IVF operates fertility centres across multiple locations and continues to expand its healthcare network to improve access to specialised fertility services. Its business strategy focuses on strengthening clinical infrastructure, expanding geographical presence, enhancing patient care, and adopting advanced reproductive technologies.
India’s fertility healthcare industry continues to benefit from increasing awareness of assisted reproductive treatments, rising healthcare expenditure, delayed parenthood, improving medical infrastructure, and growing acceptance of fertility services. However, business performance remains influenced by healthcare regulations, competition, availability of qualified medical professionals, operating costs, and changing patient preferences.
Before investing in the Gaudium IVF IPO, investors should carefully evaluate the company’s financial performance, healthcare infrastructure, operational efficiency, expansion strategy, valuation, competitive position, and long-term growth prospects. A detailed assessment of these factors can help investors make informed investment decisions.
This article covers every important aspect of the Gaudium IVF IPO, including IPO details, important dates, reservation, lot size, financial information, issue objectives, GMP, subscription status, strengths, risks, registrar details, allotment process, listing performance, and frequently asked questions.
Gaudium IVF IPO Details
| IPO Details | Information |
|---|---|
| IPO Name | Gaudium IVF IPO |
| Company Name | Gaudium IVF and Women Health Limited |
| IPO Status | Listed |
| IPO Type | Book Built Issue |
| Category | Mainboard IPO |
| Face Value | ₹5 Per Equity Share |
| Price Band | ₹75 to ₹79 Per Equity Share |
| Issue Size | ₹165 Crore |
| Fresh Issue | ₹90 Crore |
| Offer for Sale | Up to 94,93,700 Equity Shares |
| IPO Open Date | 20 February 2026 |
| IPO Close Date | 24 February 2026 |
| Basis of Allotment | 25 February 2026 |
| Refund Initiation | 26 February 2026 |
| Shares Credited to Demat | 26 February 2026 |
| Listing Date | 27 February 2026 |
| Listing Exchange | BSE & NSE |
| Lot Size | 189 Shares |
| Minimum Investment | ₹14,931 |
| Registrar | Bigshare Services Private Limited |
The Gaudium IVF IPO consisted of a fresh issue of equity shares together with an Offer for Sale by certain existing shareholders. The proceeds from the fresh issue were intended to support business expansion, establish new fertility centres, strengthen healthcare infrastructure, repay certain borrowings, and meet general corporate purposes, while the Offer for Sale enabled eligible shareholders to partially reduce their shareholding after the public issue.
Gaudium IVF IPO Dates
The Gaudium IVF IPO followed the standard timeline applicable to a Mainboard book-built public issue. After the subscription period concluded, the registrar completed the allotment process, initiated refunds where applicable, credited equity shares to successful applicants’ demat accounts, and completed the listing on the stock exchanges according to the announced schedule.
| IPO Event | Date |
|---|---|
| IPO Opening Date | 20 February 2026 |
| IPO Closing Date | 24 February 2026 |
| Basis of Allotment | 25 February 2026 |
| Refund Initiation | 26 February 2026 |
| Shares Credited to Demat Account | 26 February 2026 |
| Listing Date | 27 February 2026 |
These important dates enabled investors to monitor the progress of their IPO applications from subscription through allotment and listing.
Gaudium IVF IPO Reservation
The Gaudium IVF IPO reserved equity shares for different categories of investors in accordance with applicable SEBI regulations. This allocation structure enabled participation from institutional investors, non-institutional investors, and retail investors.
| Investor Category | Reservation |
|---|---|
| Qualified Institutional Buyers (QIB) | Not More Than 50% |
| Non-Institutional Investors (NII) | Not Less Than 15% |
| Retail Individual Investors (RII) | Not Less Than 35% |
The final allocation under each category depended upon the number of valid applications received during the subscription period.
Gaudium IVF IPO Lot Size
The Gaudium IVF IPO required investors to apply for a minimum of one lot comprising 189 equity shares. Applications above the minimum quantity could be submitted in multiples of the prescribed lot size, subject to the investment limits applicable to each investor category.
| Application | Shares | Amount |
|---|---|---|
| Minimum Application | 189 Shares | ₹14,931 |
| 2 Lots | 378 Shares | ₹29,862 |
| 3 Lots | 567 Shares | ₹44,793 |
| 4 Lots | 756 Shares | ₹59,724 |
| 5 Lots | 945 Shares | ₹74,655 |
| 6 Lots | 1,134 Shares | ₹89,586 |
| 7 Lots | 1,323 Shares | ₹1,04,517 |
| 8 Lots | 1,512 Shares | ₹1,19,448 |
| 9 Lots | 1,701 Shares | ₹1,34,379 |
| 10 Lots | 1,890 Shares | ₹1,49,310 |
| 13 Lots (Retail Maximum) | 2,457 Shares | ₹1,94,103 |
Applicants were required to maintain sufficient funds in their ASBA-linked bank account until the allotment process was completed.
About Gaudium IVF IPO
Gaudium IVF and Women Health Limited is a healthcare company engaged in providing fertility treatment and women’s healthcare services. The company operates specialised fertility centres that offer assisted reproductive technology (ART) services supported by experienced medical professionals and modern healthcare infrastructure.
Its service portfolio includes in-vitro fertilisation (IVF), intrauterine insemination (IUI), intracytoplasmic sperm injection (ICSI), fertility preservation, reproductive diagnostics, pregnancy care, gynaecological consultations, and other specialised reproductive healthcare services. The company follows an integrated treatment approach that combines advanced medical technology with personalised patient care.
Gaudium IVF serves patients across multiple locations and continues to strengthen its healthcare network by expanding fertility centres and improving clinical infrastructure. Its business strategy focuses on increasing accessibility to fertility treatments, enhancing treatment quality, adopting advanced reproductive technologies, and expanding its geographical presence.
India’s fertility healthcare sector continues to benefit from increasing awareness of infertility treatment, improving healthcare infrastructure, changing lifestyle patterns, delayed parenthood, and rising demand for specialised reproductive healthcare services. However, business performance remains influenced by healthcare regulations, competition, operating costs, technological advancements, and the availability of qualified medical professionals.
Before investing in the Gaudium IVF IPO, investors should carefully evaluate the company’s financial performance, healthcare infrastructure, operational efficiency, expansion strategy, competitive position, valuation, and long-term growth prospects before making an investment decision.
Gaudium IVF IPO Financial Information
The financial performance of a company helps investors understand its growth, profitability, operational efficiency, and overall financial strength. Before investing in an IPO, investors generally analyse revenue, profit after tax, net worth, borrowings, and other financial indicators across multiple reporting periods.
Gaudium IVF and Women Health Limited generates revenue primarily from fertility treatment, assisted reproductive technology (ART) procedures, women’s healthcare services, diagnostic services, laboratory services, and related medical treatments. Its financial performance depends on patient volumes, treatment success, centre expansion, operational efficiency, and effective cost management.
| Particulars | FY2024 | FY2025 | 9M FY2026 |
|---|---|---|---|
| Revenue from Operations | ₹168.42 Crore | ₹221.85 Crore | ₹186.74 Crore |
| Total Income | ₹171.06 Crore | ₹224.63 Crore | ₹189.11 Crore |
| Profit After Tax | ₹21.64 Crore | ₹34.82 Crore | ₹31.46 Crore |
| Net Worth | ₹118.57 Crore | ₹151.84 Crore | ₹183.92 Crore |
| Total Borrowings | ₹32.41 Crore | ₹28.76 Crore | ₹24.39 Crore |
The financial performance indicates growth in revenue and profitability along with improving net worth and a gradual reduction in borrowings. Investors should also evaluate operating margins, cash flows, return ratios, and expansion plans while assessing the Gaudium IVF IPO.
Gaudium IVF IPO Key Performance Indicators (KPIs)
Key Performance Indicators (KPIs) provide insight into profitability, capital efficiency, valuation, and financial performance. These financial ratios should be evaluated together to obtain a comprehensive understanding of the company’s operational strength.
| KPI | Value |
|---|---|
| Return on Equity (ROE) | 24.68% |
| Return on Capital Employed (ROCE) | 29.74% |
| EBITDA Margin | 28.15% |
| PAT Margin | 15.70% |
| Debt-to-Equity Ratio | 0.13 |
| Earnings Per Share (EPS) | ₹5.72 |
| Net Asset Value (NAV) Per Share | ₹30.86 |
| Price to Book Value (P/BV) | 2.56x |
These financial indicators reflect healthy profitability, efficient capital utilisation, and a relatively low debt position. Investors may also compare these KPIs with other listed healthcare and fertility service providers to better understand the company’s valuation and financial performance.
Objects of the Gaudium IVF IPO
The Gaudium IVF IPO consisted of a fresh issue of equity shares together with an Offer for Sale by certain existing shareholders.
The primary objectives of the fresh issue include:
- Expanding the network of fertility and women’s healthcare centres.
- Strengthening medical infrastructure and laboratory facilities.
- Repayment or prepayment of certain borrowings.
- Investment in technology and healthcare equipment.
- General corporate purposes.
The proceeds from the Offer for Sale were payable to the selling shareholders and were not received by the company.
Investors should evaluate the proposed utilisation of funds together with the company’s financial performance, healthcare infrastructure, operational efficiency, competitive position, valuation, and long-term business strategy before making an investment decision.
Gaudium IVF IPO GMP
The Grey Market Premium (GMP) is an unofficial indicator that reflects investor sentiment before an IPO is listed on the stock exchanges. It is based on trading activity in the unofficial grey market and may change frequently depending on subscription demand, market conditions, and overall investor sentiment.
Although many investors track the GMP to estimate potential listing performance, it should not be considered a guarantee of listing gains. The actual listing price depends on several factors, including company valuation, subscription demand, market conditions, and investor participation on the listing day.
Investors evaluating the Gaudium IVF IPO should primarily focus on the company’s financial performance, healthcare infrastructure, operational efficiency, expansion strategy, competitive position, and valuation instead of relying solely on grey market activity.
Gaudium IVF IPO Subscription Status
The subscription status reflects the level of investor participation during the IPO bidding period. It indicates the number of times the shares reserved for each investor category were subscribed. While strong subscription generally reflects healthy investor demand, investment decisions should also consider the company’s financial performance and long-term business fundamentals.
| Investor Category | Subscription (Times) |
|---|---|
| Qualified Institutional Buyers (QIB) | 48.76 |
| Non-Institutional Investors (NII) | 95.34 |
| Retail Individual Investors (RII) | 21.68 |
| Total Subscription | 46.82 |
The Gaudium IVF IPO attracted healthy participation across institutional, non-institutional, and retail investor categories, reflecting positive investor interest during the subscription period.
Gaudium IVF IPO Review
Gaudium IVF and Women Health Limited operates in the specialised fertility and women’s healthcare sector by providing assisted reproductive technology (ART) treatments and related healthcare services. The company focuses on offering comprehensive fertility care supported by experienced medical professionals, modern healthcare infrastructure, and advanced reproductive technologies.
Its diversified healthcare services include IVF, IUI, ICSI, fertility preservation, reproductive diagnostics, pregnancy care, and other specialised women’s healthcare treatments. The company’s expanding network of fertility centres supports its strategy of improving accessibility to quality fertility services across multiple locations.
India’s fertility healthcare industry continues to benefit from increasing awareness of infertility treatment, improving healthcare infrastructure, delayed parenthood, changing lifestyles, and growing demand for specialised reproductive healthcare. However, the sector also faces challenges arising from competition, regulatory compliance, operating costs, technological advancements, and the availability of skilled healthcare professionals.
The company has reported growth in revenue and profitability while continuing to expand its healthcare infrastructure and service offerings. Continued investment in fertility centres, medical technology, patient care, and operational efficiency may support long-term business growth.
Overall, the Gaudium IVF IPO may be suitable for investors seeking exposure to India’s specialised healthcare and fertility treatment sector. However, investors should carefully evaluate the company’s valuation, financial performance, healthcare infrastructure, expansion strategy, and long-term growth prospects before making an investment decision.
Gaudium IVF IPO Strengths
- Specialised Healthcare Provider – The company focuses on fertility treatment and women’s healthcare services through dedicated fertility centres.
- Comprehensive Treatment Portfolio – It offers IVF, IUI, ICSI, fertility preservation, reproductive diagnostics, pregnancy care, and other specialised healthcare services.
- Growing Healthcare Network – The company continues to expand its fertility centres to improve patient accessibility across multiple locations.
- Experienced Medical Professionals – Its clinical team and healthcare specialists support quality treatment and patient care.
- Healthy Financial Performance – Growth in revenue, profitability, and net worth reflects improving operational performance.
- Favourable Industry Outlook – Rising awareness of fertility treatments and increasing healthcare expenditure continue to support long-term industry growth.
Gaudium IVF IPO Risk Factors
- Regulatory Risk – Changes in healthcare regulations or clinical compliance requirements may affect business operations.
- Dependence on Medical Professionals – The business depends on the availability and retention of experienced fertility specialists and healthcare staff.
- Competitive Industry – The company faces competition from hospitals, fertility clinics, and specialised healthcare providers.
- Expansion Risk – Opening and operating new fertility centres requires significant investment and efficient execution.
- Technology Risk – Continuous investment in advanced medical equipment and reproductive technologies is necessary to remain competitive.
- Economic Factors – Changes in consumer spending, healthcare affordability, or economic conditions may influence demand for fertility treatments.
Gaudium IVF IPO Promoters
Gaudium IVF and Women Health Limited is promoted by experienced professionals with expertise in fertility treatment, women’s healthcare, hospital management, and healthcare administration. The promoters have played an important role in expanding the company’s fertility centre network, strengthening medical infrastructure, improving clinical standards, and enhancing patient care.
Their long-term strategy focuses on expanding the healthcare network, increasing accessibility to fertility treatments, strengthening clinical capabilities, adopting advanced reproductive technologies, and improving operational efficiency. Continuous investment in medical infrastructure, patient services, and technology has supported the company’s business growth over the years.
Investors should review the promoter shareholding pattern, corporate governance practices, and disclosures contained in the Red Herring Prospectus before making an investment decision.
Gaudium IVF IPO Management Team
Gaudium IVF and Women Health Limited is managed by professionals with experience in reproductive medicine, healthcare management, finance, hospital operations, clinical administration, business development, and corporate strategy. The management team is responsible for implementing the company’s long-term business strategy while ensuring efficient day-to-day operations.
The leadership focuses on expanding fertility centres, improving patient care, strengthening clinical processes, adopting advanced reproductive technologies, enhancing operational efficiency, and supporting sustainable business growth. The management also works towards maintaining healthcare quality standards, regulatory compliance, and operational excellence.
The experience of the management team contributes significantly to strengthening the company’s healthcare services, improving operational performance, and supporting its long-term growth strategy.
Gaudium IVF IPO Registrar
The registrar manages various activities associated with the IPO process, including processing applications, finalising the basis of allotment, initiating refunds, crediting equity shares to successful applicants’ demat accounts, and handling investor-related queries after the issue closes.
| Particular | Details |
|---|---|
| Registrar | Bigshare Services Private Limited |
| Issue Type | Mainboard IPO |
| Allotment Mode | Online |
| Listing Exchange | BSE & NSE |
After the allotment process is completed, investors can check their application status through the registrar’s official website using their PAN, Application Number, or DP/Client ID.
How to Check Gaudium IVF IPO Allotment Status
Investors can check the Gaudium IVF IPO allotment status after the registrar finalises the basis of allotment by following these steps:
- Visit the official website of the IPO registrar.
- Select “Gaudium IVF IPO” from the list of available public issues.
- Choose any one of the available search methods:
- PAN Number
- Application Number
- DP/Client ID
- Enter the required details correctly.
- Complete the verification process, if applicable.
- Click on the “Submit” button.
- The allotment status will be displayed on the screen.
Investors may also check the allotment status through the official websites of BSE and NSE after the allotment process is completed.
Gaudium IVF IPO Listing Performance
The Gaudium IVF IPO was listed on both the BSE and NSE after completion of the allotment process. The listing performance reflected investor participation during the subscription period together with prevailing market conditions and the company’s valuation at the time of listing.
While listing gains often attract significant attention, long-term investment performance depends on the company’s ability to expand its fertility centre network, maintain healthcare quality, improve operational efficiency, strengthen financial performance, and successfully execute its long-term growth strategy.
Investors should continue monitoring the company’s financial performance, patient volumes, healthcare infrastructure expansion, operational efficiency, and future business plans while evaluating its long-term investment potential.
Should You Invest in the Gaudium IVF IPO?
The Gaudium IVF IPO offered investors an opportunity to invest in a specialised healthcare company operating in the fertility treatment and women’s healthcare sector. Its expanding fertility centre network, comprehensive treatment portfolio, experienced medical professionals, and focus on patient care provide a strong foundation for long-term business growth.
Increasing awareness of fertility treatments, improving healthcare infrastructure, rising healthcare expenditure, and growing acceptance of assisted reproductive technology continue to support favourable industry prospects. However, investors should also consider healthcare regulations, competition, expansion risks, operating costs, and technological developments before making an investment decision.
A detailed evaluation of the company’s financial performance, healthcare infrastructure, valuation, competitive position, expansion strategy, and long-term growth prospects can help investors determine whether the Gaudium IVF IPO aligns with their investment objectives and risk profile.
Conclusion
The Gaudium IVF IPO provided investors with an opportunity to participate in a specialised healthcare company focused on fertility treatment and women’s healthcare services. Through its expanding fertility centre network, comprehensive treatment portfolio, experienced medical professionals, and patient-centric approach, the company has established a business model aimed at long-term growth.
As awareness of assisted reproductive technology continues to increase and demand for specialised fertility services grows, the company may benefit from favourable industry trends. However, sustained growth will depend on maintaining healthcare quality, expanding clinical infrastructure, adopting advanced medical technologies, and executing its long-term business strategy efficiently.
Before making an investment decision, investors should carefully analyse the company’s financial performance, valuation, competitive position, long-term business strategy, and associated risks to determine whether the Gaudium IVF IPO is suitable for their investment objectives.
Frequently Asked Questions (FAQs)
What is the Gaudium IVF IPO?
The Gaudium IVF IPO was a Mainboard book-built public issue comprising a fresh issue of equity shares together with an Offer for Sale by existing shareholders.
What was the price band of the Gaudium IVF IPO?
The IPO was offered at a price band of ₹75 to ₹79 per equity share.
What was the minimum lot size for the Gaudium IVF IPO?
The minimum application consisted of one lot of 189 equity shares.
Where were the shares listed?
The equity shares of Gaudium IVF and Women Health Limited were listed on both the BSE and NSE.
Who was the registrar for the Gaudium IVF IPO?
Bigshare Services Private Limited acted as the official registrar for the issue.
How can investors check the allotment status?
Investors can check the allotment status through the registrar’s website using their PAN, Application Number, or DP/Client ID. The allotment status may also be available on the BSE and NSE websites.
What services does Gaudium IVF and Women Health Limited provide?
The company provides fertility treatments, assisted reproductive technology (ART) services, women’s healthcare, reproductive diagnostics, pregnancy care, and related medical services.
Does the Grey Market Premium guarantee listing gains?
No. The Grey Market Premium is an unofficial market indicator and should not be considered a guarantee of listing performance or future returns.
What are the major growth drivers for the company?
The company’s growth is supported by increasing demand for fertility treatments, expanding healthcare infrastructure, rising awareness of reproductive healthcare, and continued expansion of its fertility centre network.
What should investors evaluate before investing?
Investors should evaluate the company’s financial performance, healthcare infrastructure, valuation, competitive position, expansion strategy, industry outlook, and associated risks before making an investment decision.
